Evolus entered into an exclusive U.S. license, supply and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin-quality applications. Evolus will fund and lead U.S. development, clinical and regulatory work and hold any FDA approval. Following approval, Evolus will purchase product under a transfer-price model with periodic adjustments and face minimum purchase requirements beginning in year four, with potential conversion to non-exclusive rights or termination if unmet. The agreement has no upfront or milestone payments and runs 15 years from first FDA approval with optional five-year renewals.
Agreement details:
- Agreement type: Exclusive U.S. license, supply and distribution agreement for Profhilo injectable HA
- Counterparty: IBSA
- Signed / Effective: Jul 07 2026 / same
- Duration / Termination: 15 years from first FDA approval; renewable in 5-year terms
- Reason: Expand aesthetics portfolio with leading skin-quality injectable
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.